NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

Revolution Medicines, Inc. (RVMDW) Stock Analysis

Revolution Medicines, Inc. (RVMDW) is a stock listed on NASDAQ and quoted in US Dollar.

RVMDW

$11.70

−$0.28 (−2.34%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on Revolution Medicines, Inc. (RVMD) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View RVMD →

Price History

Hover for the daily close. The dotted line marks the period open.

RVMDW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.39
Previous Close
$11.98
Day's Range
11.64–11.89
52-Week Range
11.64–11.89
Volume
38.02K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RVMDW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1525.00%
2025 (partial year)+0.00%

As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Visit website →